Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
July 29, 2015 at 19:00 PM EDT
[Business Wire] – NEW YORK & TOKYO–(BUSINESSWIRE)– Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,“Kyowa Hakko Kirin”) and Bristol-Myers Squibb Company (NYSE:BMY, “Bristol-Myers Squibb”) today announced that the companies have … Read more on . . . → Read More: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S. Similar Articles: Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients Company Update (NYSE:BMY): Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial Market Update (NYSE:BMY): U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma